SUPRAVENTRICULAR TACHYCARDIA IN INFANTS: DOES MEDICATION CHOICE MATTER?

BACKGROUND The etiology and mechanism of supraventricular tachycardia (SVT) are well understood, however there is no consensus on the acute treatment and medications for prevention of recurrent SVT in infants, and a number of medication choices are available. There are almost no controlled trials and medication choices are not necessarily evidence-based. The objective of this study was to compare the effectiveness of reported medication strategies for SVT in infants. METHODS AND RESULTS A registry of infants CONCLUSION Findings from this study reflect the largest cohort of infants with SVT analyzed to date. Digoxin monotherapy was used less commonly by contemporary pediatric EP doctors. There was no difference in treatment effectiveness between antiarrhythmics to support one medication over the others. The overall recurrence risks on antiarrhythmic medications in both groups were low.